Since June 2016, when CDC first issued a clinical alert on the multidrug-resistant yeast, Candida auris (C. auris), 523 clinical cases have been identified in 12 U.S. states. In 2016, CDC published guidance on identification, management, and control of C. auris and has updated the guidance as new information on this emerging organism becomes available. In the latest web update, dated December 21, 2018, found here https://www.cdc.gov/fungal/candida-auris/health-professionals.html. The notable changes include:
- A recommendation to screen patients for colonization with C. auris upon admission to a healthcare setting if they have a history of overnight hospitalization outside the United States in the last 12 months, especially 1) if hospitalized in a country with C. auris transmission, or 2) have a carbapenamase-producing organism.
- An expansion of the list of disinfectants that have been found to be effective against C. auris.
- An update on laboratory methods that will accurately identify C. auris.
Clinical infections with C. auris will be nationally notifiable starting in 2019. Please contact CDC at email@example.com for further information or questions.